<DOC>
	<DOCNO>NCT00379769</DOCNO>
	<brief_summary>This study phase 3b , multicentre , randomise , open label , parallel group study . A 4-week run-in period follow median 6 year treatment study medication addition continuation background glucose lower therapy . Patients inadequately control background metformin randomise receive , addition metformin , either rosiglitazone sulfonylurea ( glibenclamide , gliclazide glimepiride ) ratio 1:1 . Patients inadequately control background SU randomise receive , addition SU , either rosiglitazone metformin ratio 1:1 . Equal number patient receive background metformin SU entry enter study .</brief_summary>
	<brief_title>RECORD : Rosiglitazone Evaluated Cardiac Outcomes Regulation Glycaemia Diabetes</brief_title>
	<detailed_description>A RECORD follow-up study perform monitor incidence cancer bone fracture RECORD patient period 4 year end main RECORD study ( 2008 - 2012 ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients type II diabetes mellitus define 1999 World Health Organisation criterion . Glycated haemoglobin ( HbA1c ) &gt; 7.0 % = 9.0 % visit 1 . Use oral glucose lower agent minimum 6 month prior screen unchanged 2 month prior screen . Body mass index &gt; 25.0 kg/m2 . Patients receive glucose lower therapy metformin sulfonylurea . Patients systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 105 mmHg . Patients require use insulin glycaemic control time past . Hospitalisation major cardiovascular event last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>CV outcome</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>Type II diabetes</keyword>
	<keyword>sulfonylurea</keyword>
	<keyword>RECORD</keyword>
	<keyword>metformin</keyword>
</DOC>